KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:KZIA • US48669G3039

5.79 USD
+0.17 (+3.02%)
Last: Feb 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to KZIA. KZIA was compared to 525 industry peers in the Biotechnology industry. KZIA has a bad profitability rating. Also its financial health evaluation is rather negative. KZIA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • KZIA had negative earnings in the past year.
  • KZIA had a negative operating cash flow in the past year.
  • KZIA had negative earnings in each of the past 5 years.
  • In the past 5 years KZIA always reported negative operating cash flow.
KZIA Yearly Net Income VS EBIT VS OCF VS FCFKZIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -158.60%, KZIA is not doing good in the industry: 85.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROIC N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KZIA Yearly ROA, ROE, ROICKZIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KZIA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZIA Yearly Profit, Operating, Gross MarginsKZIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K -800K -1M

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • The number of shares outstanding for KZIA has been increased compared to 1 year ago.
  • The number of shares outstanding for KZIA has been increased compared to 5 years ago.
  • Compared to 1 year ago, KZIA has a worse debt to assets ratio.
KZIA Yearly Shares OutstandingKZIA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
KZIA Yearly Total Debt VS Total AssetsKZIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -13.13, we must say that KZIA is in the distress zone and has some risk of bankruptcy.
  • KZIA has a Altman-Z score of -13.13. This is in the lower half of the industry: KZIA underperforms 76.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.13
ROIC/WACCN/A
WACCN/A
KZIA Yearly LT Debt VS Equity VS FCFKZIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
  • KZIA has a worse Current ratio (0.21) than 92.95% of its industry peers.
  • A Quick Ratio of 0.21 indicates that KZIA may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.21, KZIA is not doing good in the industry: 92.57% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
KZIA Yearly Current Assets VS Current LiabilitesKZIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • KZIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.01%, which is quite impressive.
  • The Revenue for KZIA has decreased by -95.09% in the past year. This is quite bad
  • KZIA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.58% yearly.
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.16% on average over the next years. This is quite good.
  • Based on estimates for the next years, KZIA will show a very strong growth in Revenue. The Revenue will grow by 377.88% on average per year.
EPS Next Y79.58%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y15.16%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.27%
Revenue Next 5Y377.89%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • KZIA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KZIA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZIA Price Earnings VS Forward Price EarningsKZIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZIA Per share dataKZIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KZIA's earnings are expected to grow with 22.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y22.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • KZIA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (2/6/2026, 8:00:02 PM)

5.79

+0.17 (+3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)N/A
Inst Owners1.74%
Inst Owner Change22.3%
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap65.64M
Revenue(TTM)114.00K
Net Income(TTM)-28.41M
Analysts82.5
Price Target19.38 (234.72%)
Short Float %3.88%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)42.13%
EPS NY rev (3m)51.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.16
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.14
BVpS-0.23
TBVpS-1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.5%
ROA(5y)-124.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -13.13
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.76%
EPS Next Y79.58%
EPS Next 2Y35.4%
EPS Next 3Y22.59%
EPS Next 5Y15.16%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y278.64%
Revenue growth 5Y11.58%
Sales Q2Q%-98.18%
Revenue Next Year-25.37%
Revenue Next 2Y-32.53%
Revenue Next 3Y144.27%
Revenue Next 5Y377.89%
EBIT growth 1Y-55.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.03%
OCF growth 3YN/A
OCF growth 5YN/A

KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ

What is the fundamental rating for KZIA stock?

ChartMill assigns a fundamental rating of 1 / 10 to KZIA.


What is the valuation status for KZIA stock?

ChartMill assigns a valuation rating of 1 / 10 to KAZIA THERAPEUTICS-SPON ADR (KZIA). This can be considered as Overvalued.


Can you provide the profitability details for KAZIA THERAPEUTICS-SPON ADR?

KAZIA THERAPEUTICS-SPON ADR (KZIA) has a profitability rating of 0 / 10.


How financially healthy is KAZIA THERAPEUTICS-SPON ADR?

The financial health rating of KAZIA THERAPEUTICS-SPON ADR (KZIA) is 0 / 10.


What is the earnings growth outlook for KAZIA THERAPEUTICS-SPON ADR?

The Earnings per Share (EPS) of KAZIA THERAPEUTICS-SPON ADR (KZIA) is expected to grow by 79.58% in the next year.